Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Results from post-hoc analyses of the CIBIS II trial: effect of bisoprololin high-risk patient groups with chronic heart failure
Autore:
Erdmann, E; Lechat, P; Verkenne, P; Wiemann, H;
Indirizzi:
Univ Cologne, D-50924 Cologne, Germany Univ Cologne Cologne Germany D-50924 v Cologne, D-50924 Cologne, Germany Hop La Pitie Salpetriere, F-75651 Paris 13, France Hop La Pitie Salpetriere Paris France 13 riere, F-75651 Paris 13, France Merck KGaA, D-64271 Darmstadt, Germany Merck KGaA Darmstadt Germany D-64271 ck KGaA, D-64271 Darmstadt, Germany
Titolo Testata:
EUROPEAN JOURNAL OF HEART FAILURE
fascicolo: 4, volume: 3, anno: 2001,
pagine: 469 - 479
SICI:
1388-9842(200108)3:4<469:RFPAOT>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
BETA-BLOCKERS; MYOCARDIAL-INFARCTION; BLOCKADE; THERAPY; MORTALITY; RATIONALE;
Keywords:
beta-blocker; heart failure; concomitant diseases; concomitant therapy; elderly; NYHA class IV; bisoprolol;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Erdmann, E Univ Cologne, Joseph Stelzmann Str 9, D-50924 Cologne, Germany Univ Cologne Joseph Stelzmann Str 9 Cologne Germany D-50924 ny
Citazione:
E. Erdmann et al., "Results from post-hoc analyses of the CIBIS II trial: effect of bisoprololin high-risk patient groups with chronic heart failure", EUR J HE FA, 3(4), 2001, pp. 469-479

Abstract

Background: The beneficial effects of the beta -blocker bisoprolol on mortality and rate of hospitalisation as well as its safety in patients with chronic heart failure has been proven. However, its efficacy in patients in whom P-blockers have traditionally been contraindicated or caution has been advised has not been clearly determined. Therefore, analyses in high-risk subgroups of patients taking part in CIBIS II have been performed to investigate the effect of bisoprolol in elderly patients, in patients with type 2 diabetes, with renal failure, NYHA functional class IV or concomitantly treated with digitalis, aldosterone antagonists or amiodarone. Methods: High-risk subgroups of patients with chronic heart failure taking part in the CIBIS II study were retrospectively analysed with respect to mortality, hospitalisation, combined endpoint of cardiovascular mortality or hospitalisationfor cardiovascular reasons and treatment withdrawal as well as cause of death and hospitalisation. Analysis is based on intention-to-treat. Results: It was demonstrated that in spite of the expected increase in the overall risk of death and hospitalisation, patients who are diabetic, have renal impairment, NYHA class IV symptoms, are elderly, are taking either digitalis, amiodarone or aldosterone antagonists as co-medication benefit equally fromP-blockade with bisoprolol as patients without these complications or drugs. Benefit was shown for the primary endpoint all cause mortality, as well as for the secondary endpoints. Conclusions: Contrary to the hitherto prevailing doctrine of not using beta-blockers in high risk patient groups with chronic heart failure, retrospective analyses of the CIBIS II study justifythe use of this drug class in patients regardless of age, NYHA functional class, the presence of diabetes, renal impairment or concomitant treatment with digitalis, amiodarone or aldosterone antagonists. (C) 2001 European Society of Cardiology. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 01/04/20 alle ore 11:02:22